Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts
暂无分享,去创建一个
[1] Maria Pia Sormani,et al. Defining and scoring response to IFN-β in multiple sclerosis , 2013, Nature Reviews Neurology.
[2] M. Sormani,et al. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials , 2013, The Lancet Neurology.
[3] L. Kappos,et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis , 2012, Multiple sclerosis.
[4] L. Kappos,et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study , 2012, The Lancet Neurology.
[5] M Daumer,et al. Age and disability accumulation in multiple sclerosis , 2011, Neurology.
[6] P. Narayana,et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial , 2007, Annals of neurology.
[7] D. Li,et al. Randomized controlled trial of interferon-beta-1a in secondary progressive MS , 2001, Neurology.
[8] M. Trojano,et al. Age at onset in multiple sclerosis , 2000, Neurological Sciences.